|
See related Botox powd for inj information |
|
|
|
Manufacturer |
Allergan |
|
Distributor |
Maxim |
|
Contents |
Clostridium botulinum toxin type A |
|
Indications |
Listed in Dosage.
Click to view Botox detailed prescribing infomation |
|
Dosage |
Blepharospasm Initially 1.25-2.5 u inj into medial & lateral orbicularis oculi of the upper & lower lid. Initial dose: ≤25 u/eye. Additional sites in the brow area, lateral orbicularis & upper facial area may be injected if spasms interfere w/ vision. Duration of treatment: 3 mth. May repeat procedure & increase dose up to 2-fold if effect does not last for >2 mth. Management of blepharospasm: total dosing ≤100 u every 12 wk. Strabismus 0.05-0.15 mL/muscle. For vertical muscles & horizontal strabismus of <20 prism diopters: 1.25-2.5 u in any one muscle. For horizontal strabismus of 20-50 prism diopters: 2.5-5 u in any one muscle. For persistent VI nerve palsy: 1.25-2.5 u in medial rectus muscle. Residual or recurrent strabismus: Patients re-examined 7-14 days after each injection to assess effect of dose. May increase dose up to 2-folds. Max: 25 u/muscle as a single inj. Hemifacial spasm or 7th nerve disorders Treated as for unilateral blepharospasm. Cumulative dose over a 2 mth period: ≤200 u. Spasmodic torticollis (cervical dystonia) Dosing based on patient's head & neck position, localization of pain, muscle hypertrophy, body wt & response. Usual range: 95-360 u. Max: <50 u at any one site. Paed cerebral palsy 4 u/kg into the medial & lateral heads of gastrocnemius muscle of affected lower limb(s). Repeat doses every 2 mth if necessary.
Click to view Botox detailed prescribing infomation |
|
Overdosage |
View Botox overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Myasthenia gravis, Eaton-Lambert syndrome, infection at inj sites.
Click to view Botox detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Botox detailed prescribing infomation |
|
Special Precautions |
Presence of inflammation, weakness or atrophy in target muscle(s). Patients w/ amyotrophic lateral sclerosis or disorders that produce peripheral neuromuscular dysfunction. Childn <12 yr. Angle closure glaucoma. Pregnancy, lactation.
Click to view Botox detailed prescribing infomation |
|
Adverse Drug Reactions |
Corneal exposure, focal weakness, anaphylaxis, dysphagia, reactions at inj site, leg pain, weakness, skin rash, pruritus, CV effects, superficial punctate keratitis, eye dryness, blurred vision, facial droop, dizziness, tiredness, irritation, tearing, lagophthalmos, photophobia.
View ADR Monitoring Form |
|
Drug Interactions |
Effects potentiated by aminoglycosides or other drugs that interfere w/ neuromuscular transmission.
View more drug interactions with Botox |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Botox detailed prescribing infomation |
|
Storage |
View Botox storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Botox description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Botox mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Botox powder for injection |
|
|
|
Manufacturer: |
Allergan |
|
Distributor: |
Maxim |
|
 |
|
|
